專 題 乾躁症 -----------------------蔡綵景藥師 新藥介紹- Xyzal...

7
季刊 Vol.17 Num.02 1. - 乾躁症 -----------------------蔡綵景藥師 2. 新藥介紹- Xyzal® --------------------施靜妤藥師 發行人:徐弘正 發行所:仁愛醫療財團法人 輯:藥劑部 (04)24819900-1139 101 年六月出刊

Transcript of 專 題 乾躁症 -----------------------蔡綵景藥師 新藥介紹- Xyzal...

  • Vol.17 Num.02

    1. - -----------------------

    2. - Xyzal --------------------

    (04)24819900-1139

    101

  • Vol.17 Num.02

    1

    -

    Sjogrens syndrome 40~50 19

    Mucin

    pH ()

    90%

    (lymphoma)

    (Shirmers )

    ANAanti-Ro/SS-Aanti-La/SS-B

    Salagen (pilocarpine hydrochloride) Evoxac (cevimeline)

    Salagen (

  • Vol.17 Num.02

    2

    )pilocarpine hydrochloride 5mg/tab Muscarinic receptor (M1,M3)

    Salagen

    1.

    2.SJOGREN'S SYNDROME

    1.Salagen tablets 5mg

    3~6 15~30mg ( 2 ) 12

    2.Sjogren's Syndrome Salagen tablets 5mg 6

    (T )0.76Tmax1.25 Cmax 15 ng/ml

    -

    pilocarpine

    pilocarpine pilocarpine

    (atropine, inhaled ipratropium)

    pilocarpine (

    )

    C 1.

    2.

    3.4.

    SPF 15

  • Vol.17 Num.02

    3

    A

    - Xyzal

    Xyzal film-coated tablets 5mg

    5

    levocetirizine dihydrochloride 5

    Y

    H1-

    Receptor Antagonist Histamine

    Histamine

    ()

    5 ()

  • Vol.17 Num.02

    4

    5 ()

    ()

    (creatinine clearance, CLcr) CLcr serum creatinine

    CLcr =

    ( 0.85 for women )

    ()

    (hay fever)

    levocetirizine 5

    levocetirizine cetirizine

    935

    levocetirizine 5

    1% ( 1/10 1/100 )

    ( 1/100 1/1000 )

    levocetirizine 5 (8.1%)(3.1%)

    levocetirizine

    CLcr (ml/min)

    80 5079 30-49

  • Vol.17 Num.02

    5

    ()(Hemodialysis) levocetirizine

    levocetirizine

    ( CYP3A4 ) levocetirizine cetirizine pseudoephedrinecimetidineketoconazoleerythromycinazithromycinglipizide diazepam

    theophylline (400 ) cetirizine (16%) theophylline cetirizine

    levocetirizine

    ( cetirizine)

    cetirizine

    levocetirizine

    piperazine

    (creatinine clearance

  • Vol.17 Num.02

    6